StockWatch
·

Lemon Tree Hotels Ltd Q2 FY27 Results

LEMONTREEQ2 FY27 Results
Filing
Result:Very Good· Market: Flat#Margin expansion#Record quarter

Outlook: Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue361.384.9%18.0%
Total Income363.824.9%18.1%
Expenditure274.692.8%8.9%
PBT111.2240.0%99.2%
Net Profit79.7639.1%90.2%
OPM50.31%6.87pp7.63pp
NPM21.92%5.38pp8.30pp
EPS0.7224.1%63.6%
View full financials

Revenue grew a strong 18% YoY with OPM expanding ~760bps (42.7%→50.3%) driving 90% core PAT growth, a clear standout for the hotel sector with no material one-off support.

LEMON TREE HOTELS · Q2 FY27 · THE VERDICT

Record PAT, but execution caution tempers the rally

Lemon Tree delivered its best-ever Q2 profit (₹79.8 Cr, +90% YoY) with operating margins hitting 50.3%. Yet management reaffirmed guidance rather than raising it. The call reveals why: corporate demand remains muted, and the growth pillars—Aurika, Omaxe, Fleur—face meaningful execution headwinds.

17 Nov 2026 · 6 min read
Reported OPM

50.3%

includes 3.2% SAR/GST headwind

Like-to-like OPM

47.7%

+474 bps YoY; the clean underlying number

PAT Growth

+90.2%

₹79.8 Cr vs ~₹42 Cr prior Q2

Guidance Track

Reaffirmed

FY27 47%+, FY28 50%; not upgraded

On the surface, Lemon Tree posted its best-ever Q2: record PAT of ₹79.8 Cr (+90% YoY), operating margins at 50.3%, occupancy surging +633 basis points to 76.1%, and all guidance targets hit. It reads like a ramp story. But the earnings call tells a more cautious tale. Management reaffirmed guidance rather than raising it—a signal that execution risks on the company's three growth pillars (Fleur demerger, Omaxe partnership, Aurika brand scaling) are being taken seriously. Meanwhile, corporate demand, which was supposed to recover as geopolitical tensions eased, remains muted. That is the real tension: strong Q2 results sitting atop an uncertain execution roadmap and softening near-term demand for a key customer segment.

Where the profit came from

The 90% PAT growth outpaced the 18% revenue growth because of operational leverage. EBITDA grew 22% to ₹162.2 Cr as occupancy surged and the company achieved cost discipline. But the reported operating margin of 50.3% masks two headwinds. First, a 3.2% regulatory burden from retroactive GST demands and SAR provisions—real and recurring. Second, an exceptional ₹41 Cr non-cash credit from the Gurgaon hotel lease termination. Strip both, and the like-to-like operating margin is 47.7%, which validates the company's FY27 guidance ('above 47%') but also signals that underlying operational performance, while solid, is not inflated by one-time gains.

Q2 FY27 OPM breakdown, %
018.7837.5656.3450.3Reported OPM3.2SAR/GST headwind47.7Like-to-like OPM
Reported 50.3% includes a 3.2% regulatory headwind. The clean 47.7% validates management's FY27 margin guidance.
Management's key claims vs. what holds up

Best-ever second quarter, highest Q2 PAT

Supported

PAT ₹79.8 Cr (+90% YoY); prior Q2 baseline ~₹42 Cr

Like-to-like margins 47.7%, up 474 bps vs prior Q2

Supported

Reported 50.3%; adjusted 47.7% excludes 3.2% SAR/GST headwind. Validates FY27 'above 47%' target.

Revenue grew 18% with balanced occupancy and ARR mix

Supported

₹361.4 Cr delivered; ARR +8%, occupancy 76.1% (+633 bps). RevPAR +18% driven by both levers.

Corporate demand recovery underway post-geopolitical easing

Overstated

Corporate segment still muted; companies 'cutting down on discretionary travel.' IT sector hiring freezes ongoing. Management hedged H2 recovery to 55/45 retail-corporate split, with 'difficult to explain' H2 visibility.

Capex normalizing to ~1% of revenue from 2.25% in Q1

Supported

FY27 YTD capex ₹200 Cr on ~₹2,100 Cr run-rate (~9.5%); next 3.5 years ~₹3,000 Cr for new projects. Renovation dropping to 1.2% next year validates normalization target.

What changed on this call

Three material shifts from the prior quarterly narrative:

  • Corporate demand downgrade. Q1 call was optimistic on recovery; Q2 delivery shows corporate still muted, with IT sector hiring freezes and discretionary cuts offsetting leisure/MICE gains. Management now hedging H2 visibility ('difficult to explain how H2 plays out'). This is a narrative retreat.

  • Aurika Nehru Place delayed to CY31. 610-room flagship pushed from FY30 due to DDA tree-cutting approvals and environmental clearances. FY27 net keys guidance unchanged (2,000+), but timeline risk flagged. Management expects 'to make up half the time lost' post-approval.

  • Capex guidance reaffirmed, not upgraded. Total capex ₹200 Cr YTD (Bombay buyout, Shimla, Shillong). Normalization to ~1% from 2.25% Q1 is on track. Next 3.5 years ~₹3,000 Cr allocation (Omaxe, Aurika, acquisitions) highlights execution dependency. No new efficiency claim; just steady discipline.

The bull-bear ledger

What matters to holders
  • Record PAT (+90% YoY) validates operational leverage in owned assets. Occupancy surge (+633 bps to 76.1%), ARR growth (+8%), and cost discipline yielding margin expansion. Keys portfolio RevPAR +29% YoY shows the brand is maturing and pricing power is real.

  • Like-to-like margin 47.7% confirms FY27 guidance; FY28 50% target is on the roadmap. Reported 50.3% includes one-time items; underlying performance is clean. Capex discipline (1% of revenue next year) supports margin progression.

  • Asset-light strategy (Omaxe 4,000 rooms, Fleur demerger 2,500 rooms) is structurally bullish. Fee-income leverage, no capex burden, Tier 2/3 growth without capital constraints. Fleur EBITDAR margin at 53% (+112 bps YoY) shows unit economics work. Target 70%+ post-demerger is ambitious but achievable.

  • Reported profit leans on regulatory one-time items and deflagging. 3.2% SAR/GST headwind, ₹41 Cr Gurgaon lease reversal (non-cash), 530 rooms deflagged in Q2 (450 ongoing compliance review). Expect headwinds to normalize, but deflagging trajectory is fuzzy ('minimal expected' vs. 'possible owners may correct').

  • Corporate demand still muted despite macro easing. IT sector hiring freezes, discretionary travel cuts persisting. Company targeting 55/45 retail-corporate split by H2 but hedging visibility. If corporate stays weak, occupancy gains plateau and ARR becomes the only growth lever.

  • Execution risks on three growth pillars are material and unproven at scale. Aurika Nehru Place delayed 6 months (DDA risk ongoing). Omaxe depends on 3–3.5 year construction timelines in Tier 2/3 cities (unproven). Fleur demerger contingent on NCLT approval (CY27 timeline at risk). Cascading delays compress the 'prove-it' window.

  • Guidance reaffirmed, not upgraded. FY27 margins 'above 47%' (hit on like-to-like basis); FY28 50% target held without increase. This signals confidence in execution—but also management's acknowledgement of risks ahead. No aspirational upside built into guidance.

Risks, ranked by how much they should concern a holder

What could derail the story

Execution delays on growth pillars cascade

HIGH

Aurika Nehru Place (610 rooms) already 6 months behind schedule. Omaxe (4,000 rooms) depends on 3–3.5 year timelines. Fleur demerger (2,500 rooms) contingent on NCLT approval (CY27 target at risk). Delays compress the multi-year 'prove-it' window; FY28 50% margin target assumes on-schedule execution.

Corporate demand remains muted longer than expected

MEDIUM-HIGH

IT sector hiring freezes and discretionary cuts are ongoing. Corporate segment target is 55/45 split by H2, but management hedged visibility ('difficult to explain'). If corporate stays weak through H2, occupancy plateaus at 76%+ and ARR becomes the only growth lever—capping revenue upside and delaying margin progression.

Regulatory and compliance headwinds persist or intensify

MEDIUM

3.2% SAR/GST provision is real and recurring. Deflagging trajectory unclear (450 rooms ongoing, 'minimal expected' vs. 'possible owners may correct'). If compliance demands intensify or deflagging resumes, margins compress from the 47.7% clean level achieved this quarter.

Asset-light model execution depends entirely on partner performance

MEDIUM

Omaxe partnership unproven at scale (first Greater Noida project 12–18 months away). Fleur success depends on independent operators hitting 70%+ EBITDAR margin post-demerger (ambitious). Fee income is a function of partner RevPAR, not controlled by LTH. Partner stumbles become LTH stumbles.

Supply oversupply in key metro markets compresses pricing

MEDIUM-LOW

IHCL and ITC expanding aggressively in metros. Analyst flagged 'supply outpacing demand, RevPAR growth model at risk.' LTH counters with Tier 2/3 limited supply thesis and asset-light leverage—which is true—but if metros see pricing compression, blended RevPAR growth decelerates.

How the street is positioned

The stock is sending mixed signals. On the fundamental side, results are strong (record PAT, margin validation, occupancy gains). But on the positioning side, institutions are trimming exposure: FII ownership fell 119 basis points quarter-on-quarter to 18.26%, signaling net selling despite the Q2 beat. This divergence—strong earnings, weak flows—is worth parsing.

On the tape, the stock trades at ₹123.31, down 31.75% from its all-time high of ₹180.68, though it has recovered +23.79% from its 52-week low. It sits above key moving averages (SMA20 ₹114.55, SMA50 ₹110.37, SMA200 ₹113.16), and volume is increasing—suggesting accumulation despite the FII trim. RSI at 68.3 is neutral, not overbought, indicating room for upside if execution delivers.

The 31.75% drawdown from ATH is material. The stock traded at ₹180+ on the belief that Aurika, Omaxe, and Fleur would scale rapidly and re-rate the company to a higher growth multiple. The delays and corporate demand softness have reset that expectation. The current price (~₹123) reflects a more cautious path: steady margin expansion in owned assets, but slower growth pillars and near-term macro softness. FII trimming at these levels suggests they're no longer buying this thesis at current prices. This is a 'prove-it' valuation: execution on Aurika/Omaxe/Fleur will re-rate higher; stumbles will push lower. The stock is fair-priced for execution risk, not for execution upside.

The debate

What to watch next

Three concrete things that resolve the debate
  • 1 · H2 FY27 corporate demand recovery signals

    Company targeting 55/45 retail-corporate split by H2 (vs. current ~45–50% inferred). Management hedged visibility ('difficult to explain'). Watch for ARR growth ex-renovation and occupancy traction >77% as corporate bookings accelerate. If corporate stays tepid, occupancy plateaus and ARR becomes the only growth lever—capping revenue upside and validating the bear case.

  • 2 · Fleur demerger approval and 2,500-room operationalization progress

    Demerger targeted for CY27 (calendar 2027). This unlocks asset-light leverage (target 70%+ EBITDAR margin on 2,500-room portfolio). If NCLT approval slips to FY28, the catalyst delays. If approved on schedule and 2,500 rooms operationalize on time (FY30–FY31), fee-income acceleration should validate FY28 50% margin target for the blended entity.

  • 3 · Aurika/Omaxe execution and first material opening

    Watch: (a) DDA approval for Aurika Nehru Place (tree-cutting, environmental clearances); (b) Omaxe Greater Noida opening in 12–18 months and ARR achieved vs. ₹12,000 assumption; (c) speed of subsequent Omaxe projects. If timelines slip further or unit economics disappoint (ARR <₹10,000), the asset-light narrative re-rates lower and re-rating timeline extends.

Lemon Tree's Q2 is a solid, clean quarter: record PAT, margin expansion validated, occupancy surge, capex discipline all in place. But it is also a 'prove-it' quarter for a company that has reset its story from 'rapid Aurika/Omaxe growth' to 'steady margin expansion plus selective asset-light scaling.' Management's choice to maintain guidance rather than raise it reflects that realism.

The street's trim of FII exposure (down 119 bps despite strong results) tells you that institutions are pricing in execution risk on the growth pillars and macro softness on corporate demand. The 31.75% drawdown from ATH has reset expectations; the current price reflects a more cautious path.

For holders, the key number to track is the like-to-like operating margin (47.7% this quarter, 47%+ FY27 target, 50% FY28 goal). This reflects core operational health independent of regulatory one-time items. If LTH executes Aurika/Omaxe/Fleur on schedule and maintains margin momentum, re-rating to ₹140–150 is plausible. If execution stumbles or corporate demand stays weak through H2, the stock likely consolidates in the ₹115–130 range. The next two quarters are critical: H2 corporate recovery signals plus Fleur demerger progress updates will tell you which path LTH is on.

Informational and educational content only. Not investment advice.